SCHEMBL6153461

SCHEMBL6153461

COC(=O)CC1=C(C(=O)O)C(c2c(Cl)cccc2Cl)C(C(=O)O)=C(CCc2ccccc2CO)N1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.34
CYP4A11 Q02928 2/20 0.34
KDM4E B2RXH2 2/20 0.32
TTR P02766 2/20 0.32
CYP2C9 P11712 2/20 0.32
KMT2A Q03164 2/20 0.32
USP2 O75604 1/20 0.32
LMNA P02545 1/20 0.32
TBXA2R P21731 1/20 0.32
MAPK1 P28482 1/20 0.32
SLC7A5 Q01650 1/20 0.32
ALDH1A1 P00352 2/20 0.31
LDHA P00338 1/20 0.31
PTGS2 P35354 2/20 0.31
AKR1B10 O60218 1/20 0.31
UGT1A9 O60656 1/20 0.31
TRPA1 O75762 1/20 0.31
ABCB11 O95342 1/20 0.31
MT-CO2 P00403 1/20 0.31
ALB P02768 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6946876 0.92 TTR (0.35) TTRCYP2C9KMT2AUSP2LMNA
SCHEMBL6154618 0.92 KDM4E (0.36) CYP4F2CYP4A11KDM4ECYP2C9KMT2A
SCHEMBL6949307 0.90 CYP2C9 (0.32) KDM4ETTRCYP2C9KMT2AUSP2
SCHEMBL7843083 0.89 ALDH1A1 (0.41) KDM4EKMT2AUSP2ALDH1A1HPGD
SCHEMBL6153189 0.89 CYP2C9 (0.32) KDM4ETTRCYP2C9KMT2AUSP2
SCHEMBL6153144 0.88 PPARG (0.35) KMT2ALMNAALDH1A1HPGDPOLB
SCHEMBL7836265 0.87 SLC7A5 (0.39) CYP4F2CYP4A11KDM4EKMT2ALMNA
SCHEMBL6152821 0.87 KMT2A (0.31) KDM4ETTRCYP2C9KMT2AUSP2
SCHEMBL6948274 0.86 SMN1; SMN2 (0.42) KDM4ECYP2C9KMT2ALMNAMAPK1
SCHEMBL6948275 0.86 SMN1; SMN2 (0.42) KDM4ECYP2C9KMT2ALMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1307449-B1 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS PFIZER PHARMA (JP) 2005-12-07 EP disclosed
US-6653313-B2 For treatment and prevention of inflammation, asthma, allergic rhinitis, pain and other disorders WARNER-LAMBERT COMPANY LLC 2003-11-25 US disclosed
EP-1307449-A1 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS PFIZER PHARMACEUTICALS INC. (JP) 2003-05-07 EP disclosed
US-20020161006-A1 1,4-dihydropyridine compounds as bradykinin antagonists KAWAMURA MITSUHIRO (US) 2002-10-31 US disclosed
WO-2002012235-A1 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS PFIZER PHARMACEUTICALS INC. (JP) 2002-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161006-A1 1,4-dihydropyridine compounds as bradykinin antagonists BDKRB1, BDKRB2, HRH4 CYP4F2 1994/4885CYP4A11 1123/4885KDM4E 1330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.